Is Biocon overvalued or undervalued?
As of August 7, 2025, Biocon's valuation has improved to very attractive, with a PE Ratio of 51.13, an EV to EBITDA of 19.94, and a ROE of 4.40%, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, while also outperforming the Sensex with a 5.07% return over the past year.
As of 7 August 2025, Biocon's valuation grade has moved from attractive to very attractive, indicating a positive shift in its financial outlook. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 51.13, an EV to EBITDA of 19.94, and a ROE of 4.40%. In comparison to its peers, Biocon's PE Ratio is significantly higher than that of Sun Pharma Industries, which stands at 33.44, and much lower than Divi's Lab, which is at 70.6. This suggests that while Biocon is trading at a premium relative to some peers, it remains more attractive than others in the sector. Notably, Biocon's stock has outperformed the Sensex over the past year, returning 5.07% compared to the Sensex's 1.45%, reinforcing its undervalued status in the current market context.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
